239 results on '"Dickneite G"'
Search Results
2. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model
3. Improved kinetics of rIX‐FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs
4. Induction of Nadph — Diaphorase — Activity with Endotoxin in Rat Heart and Spleen in Vivo
5. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage
6. Thrombotic safety of a four-factor prothrombin complex concentrate (Beriplex P/N) for edoxaban reversal in a rabbit model: OR316
7. Four-factor prothrombin complex concentrate (Beriplex® P/N) mediated reversal of apixaban-induced bleeding in a rabbit model
8. Four-factor prothrombin complex concentrate (Beriplex® P/N) is superior to three-factor prothrombin complex concentrate for reversal of coumarin anticoagulation
9. Pre-clinical pharmacokinetic and pharmacodynamic (PK/PD) characteristics of rVIII-SingleChain, a novel recombinant single-chain FVIII: PB 4.55–6
10. Non-clinical safety and efficacy of prothrombin complex concentrates (PCC) for the reversal of dabigatran mediated anticoagulation: PB 2.48–3
11. Quantitative whole body autoradiography (QWBA) study on the biodistribution of a recombinant factor rVIIa linked to human albumin: PB 1.58–3
12. Functional characterization of rVIII-SingleChain and comparison with commercially available recombinant FVIII products: PB 1.55–6
13. Pre-clinical safety and prolonged pharmacokinetic/pharmacodynamic (PK/PD) properties of a recombinant fusion protein linking activated coagulation factor VII with albumin (rVIIa-FP): PA 4.15–4
14. Quantitative whole body autoradiography (QWBA) study on the effect of albumin fusion on the biodistribution of recombinant factor rIX: PA 1.12–1
15. Inhibiting coagulation factor XIIa potently prevents thrombosis in a rabbit arteriovenous shunt model: PA 1.10–4
16. The FXIIa inhibitor rHA-Infestin-4 safely protects from arterial and venous thrombosis in rodent and nonrodent species: PA 1.10–6
17. The coagulation factor XIIa inhibitor rHA-Infestin-4 potently improves outcome after cerebral ischemia/reperfusion injury in rats: PA 1.10–2
18. Reversal of edoxaban-induced anticoagulation by the four-factor prothrombin complex concentrate Beriplex® in a rabbit model
19. Prolonged Plasma Half-Life and Hemostatic Efficacy of a Recombinant Fusion Protein Linking Activated Coagulation Factor VII with Albumin (rVIIa-FP): PO-WE-147
20. Pre-clinical characteristics of a recombinant fusion protein linking activated coagulation factor VII with albumin (rVIIa-FP): PO-WE-148
21. Preclinical efficacy of rVIII-singlechain (CSL627), a novel recombinant FVIII: PO-TU-069
22. Preclinical pharmacokinetic characteristics of rVIII-singlechain (CSL627), a novel recombinant single-chain FVIII: PO-TU-070
23. Functional characterization and comparison of rIX-FP lots manufactured in pilot scale and full scale: PO-TU-027
24. rIX-FP, a recombinant fusion protein linking coagulation factor IX with albumin, demonstrates superior kinetics in cynomolgus monkeys and hemophilia B dogs: PO-TU-042
25. Real-time, label-free surface plasmon resonance (Biacore™) analysis of rIX-FP, a recombinant fusion protein linking coagulation factor IX with albumin, shows binding to FcRn comparable to plasma-derived human albumin - correlating with extended half-life in vivo: PO-TU-019
26. Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model
27. Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model
28. Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model
29. Immunosuppressive therapy of organ-specific nephritic autoimmune diseases with 15-deoxyspergualin
30. Inhibition of thrombin by derivatives of the dipeptide aspartic acid-amidinophenylalanine
31. Modulation of the immunoglobulin dysregulation in GvH- and SLE-like diseases by the murine IL-4 receptor (IL-4-R)
32. Disease modifying activity of 15-deoxyspergualin on acute and chronic relapsing experimental allergic encephalomyelitis as models of multiple sclerosis (MS)
33. Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis
34. Allogene Herz- und Nierentransplantation in einem starken Abstoßungsmodell mit einem neuen Immunsuppressivum, 15-Deoxyspergualin
35. Allogene Pankreas- und Inseltransplantation mit Deoxyspergualin
36. Immunostimulation as a Therapeutic Principle in Bacterial Infections: The Effect of the Immunomodulator Bestatin on the Experimental Chronic E. coli Urinary Tract Infection
37. The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats.
38. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs: Improved kinetics of rIX-FP
39. Title Page / Contents / Preface / Acknowledgements
40. Prolongation of graft survival in allogeneic islet transplantation by (−) 15-deoxyspergualin in the rat
41. Treatment of the coagulation deficit during extracorporeal circulation in a porcine model by a prothrombin complex concentrate
42. Acquired bleeding model induced by dilutional coagulopathy in the rabbit
43. Comparison of prothrombin complex concentrate and fresh frozen plasma on thrombin generation and hemorrhage in experimental dilutional coagulopathy
44. Continuous thrombin generation for monitoring phenprocoumon anticoagulation
45. Prevention of Gynaecological Adhesions using Haemostatic Fleece in a Rabbit Model
46. C1 Inhibitor for Prophylaxis of Xenograft Rejection After Pig to Cynomolgus Monkey Kidney Transplantation. Transplantation 2002: 73: 688.
47. Treatment of porcine sepsis with high-dose antithrombin III reduces tissue edema and effusion but does not increase risk for bleeding
48. HAEMODYNAMIC CHANGES UNDER POSITIONING THERAPY IN A PORCINE MODEL
49. Behaviour of human C1-inhibitor potentiated with DXS in a rat model
50. Rationale for a combination theraphy of C1 inhibitor and antithrombin III in preclinical studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.